DE29701214U1 - Trace element preparations for oral administration - Google Patents
Trace element preparations for oral administrationInfo
- Publication number
- DE29701214U1 DE29701214U1 DE29701214U DE29701214U DE29701214U1 DE 29701214 U1 DE29701214 U1 DE 29701214U1 DE 29701214 U DE29701214 U DE 29701214U DE 29701214 U DE29701214 U DE 29701214U DE 29701214 U1 DE29701214 U1 DE 29701214U1
- Authority
- DE
- Germany
- Prior art keywords
- zinc
- chromium
- substance according
- diabetics
- insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000011573 trace mineral Substances 0.000 title claims description 15
- 235000013619 trace mineral Nutrition 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title claims description 11
- 239000011701 zinc Substances 0.000 claims description 47
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 46
- 229910052725 zinc Inorganic materials 0.000 claims description 46
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 36
- 239000011651 chromium Substances 0.000 claims description 36
- 229910052804 chromium Inorganic materials 0.000 claims description 35
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 21
- 239000008103 glucose Substances 0.000 claims description 21
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 9
- 239000003792 electrolyte Substances 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 4
- 230000008092 positive effect Effects 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 235000005911 diet Nutrition 0.000 claims description 2
- 230000000378 dietary effect Effects 0.000 claims description 2
- 229960000306 zinc gluconate Drugs 0.000 claims description 2
- 239000011670 zinc gluconate Substances 0.000 claims description 2
- 235000011478 zinc gluconate Nutrition 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000003765 sweetening agent Substances 0.000 claims 2
- 150000001298 alcohols Chemical class 0.000 claims 1
- -1 anion salt Chemical class 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 150000001844 chromium Chemical class 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 239000008298 dragée Substances 0.000 claims 1
- 239000007941 film coated tablet Substances 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 235000021092 sugar substitutes Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 150000003751 zinc Chemical class 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 35
- 102000004877 Insulin Human genes 0.000 description 18
- 108090001061 Insulin Proteins 0.000 description 18
- 229940125396 insulin Drugs 0.000 description 17
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
- 210000004153 islets of langerhan Anatomy 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 102000003746 Insulin Receptor Human genes 0.000 description 3
- 108010001127 Insulin Receptor Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 238000009142 chromium supplementation Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 235000006286 nutrient intake Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 240000007591 Tilia tomentosa Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229940068911 chloride hexahydrate Drugs 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 201000002342 diabetic polyneuropathy Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- VOAPTKOANCCNFV-UHFFFAOYSA-N hexahydrate;hydrochloride Chemical compound O.O.O.O.O.O.Cl VOAPTKOANCCNFV-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000012959 renal replacement therapy Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 150000003752 zinc compounds Chemical class 0.000 description 1
- 229940021724 zinc gluconate trihydrate Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229940091251 zinc supplement Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
27,1.199727,1.1997
GEBRAUCHSMUSTERANMELDUNGUTILITY MODEL REGISTRATION
DR. VOLKER STEUDLEDR. VOLKER STEUDLE
Giessener Str.115Giessener Str.115
D-35440 LindenD-35440 Linden
SPURENELEMENTPRÄPARAT ZUR ORALEN VERABREICHUNGTRACE ELEMENT PREPARATION FOR ORAL ADMINISTRATION
• j 3j• j 3j
Die Erfindung betrifft die Verwendung eines Spurenelementpräparates, enthaltend die Spurenelemente Zink und Chrom als Elektrolyte, zur oralen Verabreichung für Patienten mit Diabetes mellitus, um die Glucosetoleranz zu verbessern.The invention relates to the use of a trace element preparation containing the trace elements zinc and chromium as electrolytes for oral administration to patients with diabetes mellitus in order to improve glucose tolerance.
In der Bundesrepublik Deutschland leben nach Angaben der Deutschen Diabetes Gesellschaft (DDG) momentan circa 4 Mio. Diabetiker (5 % Typ I Diabetiker insulinabhängig, 95 % Typ M Diabetiker - insulinunabhängig). Im Jahr 2000 wird sich diese Zahl verdoppeln. Diabetes mellitus kommt in einem besonders hohen Prozentsatz (über 30 %) bei Patienten unter Nierenersatztherapieverfahren (Niereninsuffizienz mit Dialyse, Nierentransplantierte) vor. Die Hyperglykämie (erhöhte Blutglucose) kennzeichnet als Kardinalsymptom den Diabetes mellitus (gestörte Glucosetoleranz). Bei Diabetikern liegt entweder ein Insulinmangel (Typ I) und/oder eine Insulinresistenz (Typ II) vor. Insulin reguliert den Blutglucosespiegel.According to the German Diabetes Society (DDG), there are currently around 4 million diabetics living in the Federal Republic of Germany (5% type I diabetics are insulin-dependent, 95% type M diabetics are insulin-independent). This number will double in 2000. Diabetes mellitus occurs in a particularly high percentage (over 30%) of patients undergoing renal replacement therapy (renal insufficiency with dialysis, kidney transplant recipients). Hyperglycemia (increased blood glucose) is the cardinal symptom of diabetes mellitus (impaired glucose tolerance). Diabetics either have an insulin deficiency (type I) and/or insulin resistance (type II). Insulin regulates the blood glucose level.
Spurenelemente können keinen Diabetiker heilen oder alleinig therapieren. Trotzdem spielen die lebensnotwendigen Spurenelemente Chrom und Zink eine entscheidende Rolle bei der Blutzuckerregulation.Trace elements cannot cure diabetics or treat them alone. Nevertheless, the vital trace elements chromium and zinc play a crucial role in blood sugar regulation.
"Chrom und möglicherweise eine chromhaltige, in der Nahrung vorkommende, als Glucosetoleranzfaktor bezeichnete Substanz haben eine Beziehung zum Glucosestoffwechsel" (Zitat aus Kasper, H.: Ernährungsmedizin und Diätetik, 8. Aufl., S. 61, Verlag Urban und Schwarzenberg, München 1996). Im Tierversuch finden sich eine verminderte Glucosetoleranz und ein um 50 % reduzierter Einbau von Glucose in Muskel- und Leberglykogen bei Chrommangel. Chrom muss offenbar zugegen sein , damit Insulin seine Wirkung an der Zeile entfalten kann. In Studien konnte die Blutglucoseeinstellung bei erwachsenen Diabetikern durch tägliche Gabe von 180-1000 &mgr;g Chrom verbessert werden. Die genauen biochemischen Wirkmechanismen sind noch nicht ausreichend bekannt. "Chromium and possibly a chromium-containing substance found in food and known as the glucose tolerance factor have a relationship to glucose metabolism" (quote from Kasper, H.: Nutritional Medicine and Dietetics, 8th edition, p. 61, Urban and Schwarzenberg Publishing, Munich 1996). Animal experiments have shown reduced glucose tolerance and a 50% reduction in the incorporation of glucose into muscle and liver glycogen in cases of chromium deficiency. Chromium must obviously be present for insulin to have its effect on the cells. In studies, blood glucose control in adult diabetics could be improved by daily administration of 180-1000 μg of chromium. The exact biochemical mechanisms of action are not yet sufficiently known.
Den täglichen Chrombedarf für gesunde Erwachsene gibt die Deutsche Gesellschaft für Ernährung (DGE) mit 50-200 pg an. Die tatsächliche Zufuhr liegt mit durchschnittlich 50 pg an der unteren Grenze der Empfehlungen. Die DGE schließt in ihren Empfehlungen für die Nährstoffzufuhr von 1991 darauf, daß bei gestörter Glucosetoleranz eine Verbesserung durch Chromzulagen erzielt werden (DGE: Empfehlungen für die Nährstoffzufuhr. Umschau Verlag, Frankfurt, 1991). Das Ergebnis trifft für beide Diabetestypen zu. Die Insulin-Rezeptor-Bindung und Glucoseeinschleusung in die Zellen ist unter Chromgabe deutlich verbessert. Da dieThe German Nutrition Society (DGE) states that the daily chromium requirement for healthy adults is 50-200 pg. The actual intake is at the lower limit of the recommendations, with an average of 50 pg. In its 1991 recommendations for nutrient intake, the DGE concludes that in cases of impaired glucose tolerance, an improvement can be achieved by supplementing chromium (DGE: Recommendations for nutrient intake. Umschau Verlag, Frankfurt, 1991). This result applies to both types of diabetes. Insulin receptor binding and glucose transport into the cells are significantly improved with chromium administration. Since the
Chromversorgung über Nahrungsmittel in Deutschland nicht optimal ist, ist eine Chromgabe über Chrompräpafate (Tabletten)-sinnvoll,Chromium supply through food in Germany is not optimal, it is sensible to take chromium through chromium preparations (tablets).
Das ebenfalls essentielle Spurenelement Zink ist vielen Diabetikern als Komplexbildner in zinkverzögerten Insulinen bekannt. Zink verbessert die Insulinspeicherung bei Typ Il Diabetikern. Zinkmangel hemmt die Insuiinaktivität und die Insulinrezeptorbildung.The equally essential trace element zinc is known to many diabetics as a complexing agent in zinc-delayed insulins. Zinc improves insulin storage in type II diabetics. Zinc deficiency inhibits insulin activity and insulin receptor formation.
Der Zinkbedarf beträgt laut DGE im Erwachsenenalter 12-15 mg täglich für Gesunde. Die tägliche durchschnittliche Zinkaufnahme über Nahrungsmittel liegt unter dieser Empfehlung. Diabetiker gehören zu den Risikogruppen der Zinkversorgung. Die Urin-Zink-Verluste sind bei Diabetikern deutlich gesteigert. Dies trifft insbesondere auf Diabetiker zu, die unter diabetischer Nephropathie leiden. In einer Studien findet sich eine Urin-Zink-Ausscheidung, die bei Diabetikern im Vergleich zu Gesunden um 50-150 % gesteigert ist. Bei positiven Harnzuckerwerten ist der Zinkverlust noch stärker gesteigert und kann das zwei- bis dreifache der Norm überschreiten. Bei Typ Il - Diabetikern fanden sich nach 6 Wochen unter Zinkgabe (2 &khgr; 6,3 mg Zink/Tag) eine Senkung der durchschnittlichen Nüchternblutzuckerwerte von 250 auf 112 mg/dl Blut. In anderen Studien fällt sowohl der Nüchtern- als auch der postprandiaie (nach einer Mahlzeit) Blutgiucosespiegel unter Zinkeinnahme deutlich ab. Daher scheint die Einnahme von 15 mg Zink täglich über Zinkpräparate (Tabletten) sinnvoll. Zink wird aus organischen Verbindungen deutlich besser resorbiert als aus anorganischen (z. B. Zinksulfat, Zinkchlorid). Die Zinksupplementierung sollte daher mit organischen Zinkverbindungen, wie z. B. Zinkglukonat erfolgen.According to the DGE, the zinc requirement in adulthood is 12-15 mg per day for healthy people. The average daily zinc intake from food is below this recommendation. Diabetics are one of the risk groups for zinc supply. Urinary zinc losses are significantly increased in diabetics. This is particularly true for diabetics who suffer from diabetic nephropathy. In one study, urinary zinc excretion was found to be 50-150% higher in diabetics than in healthy people. If urine sugar levels are positive, zinc loss is even higher and can be two to three times higher than the norm. In type II diabetics, a reduction in average fasting blood sugar levels from 250 to 112 mg/dl of blood was found after 6 weeks of zinc administration (2 x 6.3 mg zinc/day). In other studies, both fasting and post-meal (after a meal) blood glucose levels drop significantly when zinc is taken. Therefore, taking 15 mg of zinc daily in the form of zinc supplements (tablets) seems to make sense. Zinc is absorbed much better from organic compounds than from inorganic ones (e.g. zinc sulfate, zinc chloride). Zinc supplementation should therefore be carried out with organic zinc compounds, such as zinc gluconate.
Zudem leiden Diabetiker häufig unter dem sogenannten "diabetischen Fuß", resultierend aus schlechten Blutglucosewerten, peripherer Verschlusskrankheit und diabetischer Polyneuropathie.In addition, diabetics often suffer from the so-called "diabetic foot", resulting from poor blood glucose levels, peripheral arterial disease and diabetic polyneuropathy.
Unter Zinkgabe bessern sich diese Symptome deutlich, Wunden heilen besser ab. Dies ist unter anderem auf den immunmodulatorischen bzw. entzündungshemmenden Effekt von Zink zurückzuführen (praktische Anwendung von Zinksalbe).When zinc is administered, these symptoms improve significantly and wounds heal better. This is due, among other things, to the immunomodulatory and anti-inflammatory effects of zinc (practical application of zinc ointment).
Zink- und/oder Chrommangel löst zwar keinen Diabetes mellitus aus und heilt keinen Diabetiker. Zink- und/oder Chromgabe sind lediglich eine sinnvolle Maßnahme der zusätzlichen Diabetestherapie. Die beiden Spurenelemente verbessern die Blutzuckereinstellung signifikant. Dies trifft insbesondere für Patienten mitZinc and/or chromium deficiency does not cause diabetes mellitus and does not cure diabetics. Zinc and/or chromium supplementation is merely a useful measure of additional diabetes therapy. The two trace elements significantly improve blood sugar control. This is especially true for patients with
Insulinresistenz (Typ Il-Diabetiker) zu, da Zink und Chrom die Insulinrezeptoren positiv beeinflussen.Insulin resistance (type II diabetics) increases because zinc and chromium have a positive effect on insulin receptors.
Effekte einer zusätzlichen Zink-/Chromzufuhr treten erst nach ca. sechs Wochen regelmäßiger Einnahme ein (Dauer der Proteinbiosynthese von zinkhaltigen oder zink- / chromabhängigen Metalloenzymen bzw. Hormonen). Sinnvoll ist die Einnahme eines Kombinationspräparates postprandial morgens eine Stunde nach dem Frühstück und/oder abends vor dem Schlafengehen.The effects of additional zinc/chromium intake only occur after about six weeks of regular intake (duration of protein biosynthesis of zinc-containing or zinc/chromium-dependent metalloenzymes or hormones). It is sensible to take a combination preparation postprandially in the morning one hour after breakfast and/or in the evening before going to bed.
Zusammenfassende Wirkungen auf die Glucosetoleranz von Zink und Chrom:Summary of effects of zinc and chromium on glucose tolerance:
(t = erhöht, i = vermindert)(t = increased, i = decreased)
1. Insulinsynthese der beta-Zeiien der Langerhans'schen Inseln T1. Insulin synthesis of the beta cells of the islets of Langerhans T
2. Insulinsekretion aus den beta-Zellen t2. Insulin secretion from the beta cells t
3. Insulinspeicherkapazität des endokrinen Pankreas t3. Insulin storage capacity of the endocrine pancreas t
4. Insulinaktivität T
5.Rezeptorsensitivität gegenüber insulin t 4. Insulin activity T
5.Receptor sensitivity to insulin t
6. Rezeptorfunktion t6. Receptor function t
7. Insulinresistenz 4-7. Insulin resistance 4-
8. Glukoseaufnahme in die Zeile T8. Glucose uptake in line T
Ergebnis für die Glucosetoleranz: Blutglucosespiegel 4- und Insulinwirkung t.Result for glucose tolerance: blood glucose level 4- and insulin action t.
Die Wirkungsansätze einer Zink-/Chromgabe bei Diabetikern sind in der Tab. zusammengefasst.The effects of zinc/chromium administration in diabetics are summarized in the table.
Tab.1: Wirkungsansätze einer Zink-/Chromgabe bei Typ I- und Typ Il-Diabetikern Tab.1: Effects of zinc/chromium supplementation in type I and type II diabetics
Typ! Typ IiType! Type Ii
1. Insulinsynthese der beta-Zellen der Langerhans'schen Inseln t +1. Insulin synthesis of the beta cells of the islets of Langerhans t +
2. Insulinsekretion aus den beta-Zellen t +2. Insulin secretion from the beta cells t +
3. Insulinspeicherkapazität des endokrinen Pankreas t - +3. Insulin storage capacity of the endocrine pancreas t - +
4. Insulinaktivität t - +4. Insulin activity t - +
5. Rezeptorsensitivität gegenüber Insulin t + +5. Receptor sensitivity to insulin t + +
6. Rezeptorfunktion t + +6. Receptor function t + +
7. Insulinresistenz 4 + +7. Insulin resistance 4 + +
8. Glukoseaufnahme in die Zelle t + +8. Glucose uptake into the cell t + +
Glucosetoleranz: Blutglucosespiegel 4 und Insulinwirkung t + +Glucose tolerance: blood glucose level 4 and insulin action t + +
Zinkhaltige Präparate verbessern die Glucosetoleranz bei Diabetikern. Ebenfalls wird die Glucosetoleranz duch eine vermehrte Chromzufuhr verbessert (Übersicht in: Winterberg, B. ,. Bocchcchio, M., Hossdorf, Th., Lahl, H., Lison, A. E., Zumkley, H.: Preparations containing zinc improve glucose tolerance in diabetics. Glucose tolerance is also improved by an increased intake of chromium (review in: Winterberg, B., Bocchcchio, M., Hossdorf, Th., Lahl, H., Lison, AE, Zumkley, H.:
Zinc in the treatment of diabetic patients. Trace Elements in Medicine, 6 (4), 173-177, 1989. Mooradian, A. 9T7-FaHIa, M., Hoegwerf, B., Maryniuk, M., Wylie-Rosett, J.: Selected Vitamins and Minerals in Diabetics. Diabetes Care, 17 (5) 464-479, 1994). Synergistische Effekte von Zink und Chrom, die die Glukosetoleranz bei Diabetikern verbessern, sind bislang nicht bekannt. Spurenelementpräparate mit Zink- und Chromgehalt für Diabetiker sind bislang nicht beschrieben. Zinc in the treatment of diabetic patients. Trace Elements in Medicine, 6 (4), 173-177, 1989. Mooradian, A. 9T 7 -FaHIa, M., Hoegwerf, B., Maryniuk, M., Wylie-Rosett, J.: Selected Vitamins and Minerals in Diabetics. Diabetes Care, 17 (5) 464-479, 1994). Synergistic effects of zinc and chromium that improve glucose tolerance in diabetics are not yet known. Trace element preparations containing zinc and chromium for diabetics have not yet been described.
Der im Schutzanspruch 1 angegebenen Erfindung liegt das Problem zugrunde, ein Präparat mit den Spurenelementen Zink und Chrom zu schaffen, die in der Kombination von Zink und Chrom die Glucosetoleranz bei Diabetikern deutlich verbessert.The invention specified in claim 1 is based on the problem of creating a preparation with the trace elements zinc and chromium, which, in combination with zinc and chromium, significantly improves glucose tolerance in diabetics.
Dieses Problem wird mit den im Schutzanspruch 1 aufgeführten Merkmalen gelöst.This problem is solved with the features listed in claim 1.
Mit der Erfindung wird erreicht, daß die Glucosetoleranz bei Diabetikern, sowohl durch die positiven Effekte von Zink, als auch durch die positiven Effekte von Chrom, in Kombination von Zink und Chrom in einem Spurenelementpräparat vorteilhaft verbessert werden.The invention achieves that the glucose tolerance in diabetics is advantageously improved both through the positive effects of zinc and through the positive effects of chromium, in combination of zinc and chromium in a trace element preparation.
Vorteilhafte Ausgestaltungen der Erfindung sind in den Schutzansprüchen 2-8 angegeben.Advantageous embodiments of the invention are specified in claims 2-8.
Ein Ausführungsbeispiel der Erfindung wird anhand folgenden Beispiels erläutert.An embodiment of the invention is explained using the following example.
Zusammensetzung einer Tablette:Composition of one tablet:
117 mg Zinkglukonattrihydrat (USP 23) werden mit 1,025 mg Chrom-(NI)-chloridhexahydrat (USP 23) zusammen mit 206,025 mg Sorbit und 25 mg pflanzliche Fette gemischt und, entsprechend den Regeln zur pharmazeutischen Herstellung von Tabletten, zu Tabletten ä 350 mg Gewicht mit einem Durchmesser von 10 mm, gewölbt, verpresst.117 mg of zinc gluconate trihydrate (USP 23) are mixed with 1.025 mg of chromium (NI) chloride hexahydrate (USP 23) together with 206.025 mg of sorbitol and 25 mg of vegetable fats and, in accordance with the rules for the pharmaceutical manufacture of tablets, are pressed into tablets weighing 350 mg with a diameter of 10 mm, convex.
1 Tablette, als Einzeldosis, enthält 15 mg Zink (als Elektrolyt Zn2+) und 200 pg Chrom (als Elektrolyt Cr3+).1 tablet, as a single dose, contains 15 mg zinc (as electrolyte Zn 2+ ) and 200 pg chromium (as electrolyte Cr 3+ ).
Spurenelementpräparat zur oralen Verabreichung mit Zink und Chrom als wirksame Substanz, sowie gegebenenfalls zusätzlichen organischen oder anorganischen Zusatzstoffen.Trace element preparation for oral administration with zinc and chromium as the active substance, and optionally additional organic or inorganic additives.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE29701214U DE29701214U1 (en) | 1997-01-27 | 1997-01-27 | Trace element preparations for oral administration |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE29701214U DE29701214U1 (en) | 1997-01-27 | 1997-01-27 | Trace element preparations for oral administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE29701214U1 true DE29701214U1 (en) | 1997-03-27 |
Family
ID=8035006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE29701214U Expired - Lifetime DE29701214U1 (en) | 1997-01-27 | 1997-01-27 | Trace element preparations for oral administration |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE29701214U1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1364647A4 (en) * | 2001-01-31 | 2006-04-05 | Japan Science & Tech Agency | HYPOGLYKEMIC AGENT |
-
1997
- 1997-01-27 DE DE29701214U patent/DE29701214U1/en not_active Expired - Lifetime
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1364647A4 (en) * | 2001-01-31 | 2006-04-05 | Japan Science & Tech Agency | HYPOGLYKEMIC AGENT |
| US7226935B2 (en) | 2001-01-31 | 2007-06-05 | Japan Science And Technology Corporation | Hypoglycemic agent |
| EP1897541A3 (en) * | 2001-01-31 | 2008-05-28 | Japan Science and Technology Agency | Hypoglycemic agent |
| EP1900366A3 (en) * | 2001-01-31 | 2008-06-25 | Japan Science and Technology Agency | Hypoglycemic agent |
| EP1905438A3 (en) * | 2001-01-31 | 2008-07-02 | Japan Science and Technology Agency | Hypoglycemic agent |
| EP1900367A3 (en) * | 2001-01-31 | 2008-07-02 | Japan Science and Technology Agency | Hypoglycemic agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0046167B1 (en) | Nutrient solution for complete extra-buccal feeding and for an enhanced production of energy, and manufacturing process | |
| DE3872878T2 (en) | TREATMENT OF DIABETES BY COMBINED INSULIN FORMS. | |
| CH653891A5 (en) | MEANS FOR ORAL ADMINISTRATION TO A HUMAN AND / OR MAMMAL. | |
| EP1037648A2 (en) | The use of erythropoietin and iron preparations for producing pharmaceutical combination preparations for treating rheumatic diseases | |
| DE3040780C2 (en) | Use of a pharmaceutical composition for the treatment of diabetes | |
| DE69728163T2 (en) | COMPOSITION OF AMINO ACIDS | |
| EP2734217A1 (en) | Product for the parenteral nutrition of obese intensive-care patients | |
| EP0851762A1 (en) | Pharmaceutical combination preparations containing erythropoietin and iron preparations | |
| Shils | Minerals in total parenteral nutrition | |
| DE60032509T2 (en) | CHROMI-HISTIDINE COMPLEXES AS FOOD ADDITIVES | |
| EP3135273B1 (en) | Mineral compositions for stimulating carbohydrate metabolism | |
| DE602004005455T2 (en) | METHOD FOR TREATING OR PREVENTING CHRONIC WOUNDS AND COMPLETE FOOD COMPOSITION WITH GLYCIN AND / OR LEUCINE FOR USE THEREIN | |
| EP2731454A1 (en) | Dietetic multi-component system | |
| DE3421644C2 (en) | ||
| DE29701214U1 (en) | Trace element preparations for oral administration | |
| DE3316726A1 (en) | Therapeutically active mixture | |
| Blalock Jr et al. | Role of diet in the management of vasopressin-responsive and-resistant diabetes insipidus | |
| EP0834318B1 (en) | Composition comprising chromium for controlling cellular glucose uptake | |
| DE3115322A1 (en) | PHARMACEUTICAL OR. DIAGNOSTICALLY OR AS A FOOD ADDITIVE EFFECTIVE OR APPLICABLE AGENT | |
| DE9412374U1 (en) | Food supplements | |
| DE3936319C3 (en) | Phosphate binder for oral administration | |
| CH665773A5 (en) | NEPHROLOGICAL-UROLOGICAL MEDICINAL PRODUCT. | |
| DE19534602C2 (en) | Use of threonine to treat phenylketonuria | |
| CN100344291C (en) | Nutritive lead discharging oral liquid and its preparation method | |
| EP1675598B1 (en) | Nutrition trace element composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R086 | Non-binding declaration of licensing interest | ||
| R207 | Utility model specification |
Effective date: 19970507 |
|
| R150 | Utility model maintained after payment of first maintenance fee after three years |
Effective date: 20001127 |
|
| R151 | Utility model maintained after payment of second maintenance fee after six years |
Effective date: 20030820 |
|
| R157 | Lapse of ip right after 6 years |
Effective date: 20030801 |
|
| R153 | Extension of term of protection rescinded |
Effective date: 20040422 |